Ardsley, N.Y.-based Acorda Therapeutics Inc. said the U.S. Food and Drug Administration approved its Parkinson's treatment Inbrija.

Inbrija is a formulation of one of the main drugs used to treat Parkinson's — levodopa. It will be used in patients experiencing so-called off periods, when the effects of an existing medication start to wear off in between doses, or the re-emergence of Parkinson's symptoms.

Acorda's medicine will be commercially available during the first quarter of 2019.